Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRedx Pharma Regulatory News (REDX)

Share Price Information for Redx Pharma (REDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.00
Bid: 8.00
Ask: 10.00
Change: -1.00 (-10.00%)
Spread: 2.00 (25.00%)
Open: 9.00
High: 9.00
Low: 8.25
Prev. Close: 10.00
REDX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Redx Pharma Plc

15 Jan 2020 15:17

RNS Number : 9329Z
Sarah Hooker
15 January 2020
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Sarah Hooker

Dennis Hallahane

Paulene Hallahane

Bridget Hallahane

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Redx Pharma Plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

N/A

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

14 January 2020

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

1p Ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

2,225,100

1.76

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

2,225,100

1.76

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

15 January 2020

Contact name:

Sarah Hooker

Telephone number*:

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETGPURUGUPUGAA
Date   Source Headline
17th Sep 202111:06 amRNSSecond Price Monitoring Extn
17th Sep 202111:00 amRNSPrice Monitoring Extension
16th Sep 202112:16 pmRNSPrice Monitoring Extension
16th Sep 202112:15 pmRNSSecond Price Monitoring Extn
16th Sep 202112:12 pmRNSSecond Price Monitoring Extn
16th Sep 202112:08 pmRNSPrice Monitoring Extension
14th Sep 20212:05 pmRNSSecond Price Monitoring Extn
14th Sep 20212:00 pmRNSPrice Monitoring Extension
14th Sep 202111:05 amRNSSecond Price Monitoring Extn
14th Sep 202111:00 amRNSPrice Monitoring Extension
13th Sep 20217:00 amRNSRXC004 Phase 1 data to be presented at ESMO 2021
2nd Sep 20217:00 amRNSMilestone Payment from Jazz Pharmaceuticals
27th Jul 20217:00 amRNSRedx Announces Phase 2 Dose Selection of RXC004
8th Jul 20211:43 pmRNSExercise of Options and Total Voting Rights
1st Jul 202111:08 amRNSNew Grant of Options and Director/PDMR Dealing
17th Jun 20217:00 amRNSRedx Receives Milestone Payment for RXC006
7th Jun 20217:00 amRNSInterim results for the six months ended 31 March
4th Jun 20217:00 amRNSChange of Auditor
3rd Jun 20217:00 amRNSFirst Subject Dosed in Phase 1 Study with RXC007
1st Jun 20217:00 amRNSDirectorate Change
24th May 20217:00 amRNSNotice of Interim Results
19th May 20217:00 amRNSAppointment of Non-Executive Director
5th May 20217:00 amRNSAppointment of Peter Collum as CFO
30th Apr 20219:00 amRNSConfirmation of post offer intention statements
28th Apr 20217:00 amRNSDosing of first patients with RXC004 and Anti-PD1
29th Mar 20219:00 amRNSRedx to present at AACR
15th Mar 20217:00 amRNSAppointment of Joint Broker
2nd Mar 202112:38 pmRNSResult of AGM and Directorate change
1st Mar 20219:57 amRNSNew Grant of Options
25th Feb 20217:00 amRNSPresentation at Cowen Healthcare Conference
5th Feb 20215:23 pmRNSNotice of AGM
27th Jan 20217:00 amRNSFinal Results for the Year Ended 30 September 2020
14th Jan 20217:00 amRNSNotice of Preliminary Results
29th Dec 20207:00 amRNSTR-1: Notification of major holdings
23rd Dec 20209:00 amRNSShare Purchases by Directors
22nd Dec 20205:13 pmRNSTR-1: Notification of major holdings
22nd Dec 20208:30 amRNSAdmission of Placing
21st Dec 202012:26 pmRNSResults of Open Offer and General Meeting
2nd Dec 20207:10 amRNSNew Grant of Options
2nd Dec 20207:00 amRNSPlacing and Open Offer Announcement
27th Oct 20207:00 amRNSAppointment of Chief Medical Officer
9th Sep 20207:00 amRNSResearch collaboration with Jazz Pharmaceuticals
3rd Sep 20203:00 pmRNSTR-1: Notification of major holdings
17th Aug 20202:05 pmRNSSecond Price Monitoring Extn
17th Aug 20202:00 pmRNSPrice Monitoring Extension
5th Aug 20207:00 amRNSAppointment of NED and changes to Board committees
4th Aug 20207:37 amRNSOut licensing agreement with AstraZeneca
20th Jul 202011:35 amRNSResult of General Meeting
2nd Jul 20202:05 pmRNSSecond Price Monitoring Extn
2nd Jul 20202:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.